Thomas Leggett Biography and Net Worth

Chief Financial Officer of Stoke Therapeutics

Tommy Leggett is the chief financial officer (CFO) of Stoke Therapeutics where he oversees all aspects of the company’s financial strategy and operations. He is also responsible for overseeing Stoke’s business development activities.

Tommy has more than 20 years of experience as a biotechnology executive, board member, and investment banker. He has led financial strategy and operations and secured financing for dozens of life science companies. Prior to joining Stoke, Tommy served as CFO of Affinia Therapeutics. Before joining Affinia Therapeutics, Tommy was CFO at Black Diamond Therapeutics, where he led the company’s Series C financing and initial public offering (IPO). Prior to Black Diamond, he served as CFO at Axcella Health, where he helped raise capital across three financings, including an IPO. Before joining the biotechnology industry, Tommy spent more than a decade as an investment banker for the healthcare groups at J.P. Morgan Securities, Lazard Frères & Company, and UBS Securities. Tommy currently serves on the board of directors of Clover Biopharmaceuticals, Ltd.

Tommy received a B.A. in economics from Columbia University and an M.B.A. in finance from the Wharton School at the University of Pennsylvania.

What is Thomas Leggett's net worth?: The estimated net worth of Thomas Leggett is at least $340.86 thousand as of March 18th, 2026. Mr. Leggett owns 10,172 shares of Stoke Therapeutics stock worth more than $340,864 as of March 23rd. This net worth approximation does not reflect any other assets that Mr. Leggett may own. Learn More about Thomas Leggett's net worth.
How old is Thomas Leggett?: Mr. Leggett is currently 47 years old. There are 5 older executives and 2 younger executives at Stoke Therapeutics. The oldest executive at Stoke Therapeutics is Dr. Edward M. Kaye M.D., Ph.D., CEO & Director, who is 75 years old. Learn More on Thomas Leggett's age.
How do I contact Thomas Leggett?: The corporate mailing address for Mr. Leggett and other Stoke Therapeutics executives is 45 WIGGINS AVENUE, BEDFORD MA, 01730. Stoke Therapeutics can also be reached via phone at (781) 430-8200 and via email at [email protected]. Learn More on Thomas Leggett's contact information.
Has Thomas Leggett been buying or selling shares of Stoke Therapeutics?: Within the last three months, Thomas Leggett has sold $147,141.84 of Stoke Therapeutics stock. Most recently, Thomas Leggett sold 2,382 shares of the business's stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $31.34, for a transaction totalling $74,651.88. Following the completion of the sale, the chief financial officer now directly owns 10,172 shares of the company's stock, valued at $318,790.48. Learn More on Thomas Leggett's trading history.
Who are Stoke Therapeutics' active insiders?: Stoke Therapeutics' insider roster includes Jonathan Allan (General Counsel), Jason Hoitt (Chief Patient Officer), Edward Kaye (), Edward Kaye (Director), Adrian Krainer (Director), Thomas Leggett (Chief Financial Officer), Arthur Levin (Director), Huw Nash (COO), Barry Ticho (Insider), and Arthur Tzianabos (Insider). Learn More on Stoke Therapeutics' active insiders.
Are insiders buying or selling shares of Stoke Therapeutics?: In the last twelve months, insiders at the sold shares 42 times. They sold a total of 367,800 shares worth more than $9,809,384.63. The most recent insider tranaction occured on March, 19th when insider Barry Ticho sold 1,461 shares worth more than $43,815.39. Insiders at Stoke Therapeutics own 9.5% of the company. Learn More about insider trades at Stoke Therapeutics.
Information on this page was last updated on 3/19/2026.

Thomas Leggett Insider Trading History at Stoke Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/18/2026	Sell	2,382	$31.34	$74,651.88	10,172
3/17/2026	Sell	2,196	$33.01	$72,489.96	12,554

Thomas Leggett Buying and Selling Activity at Stoke Therapeutics

Stoke Therapeutics Company Overview

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Today's Range

Now: $34.47

$34.91

50 Day Range

MA: $32.61

$28.70

$38.35

2 Week Range

Now: $34.47

$5.35

$40.22

Volume

17,588 shs

Average Volume

764,054 shs

Market Capitalization

$2.04 billion

P/E Ratio

51.25

Dividend Yield

N/A

Beta

1.07

Thomas Leggett Biography and Net Worth

What is Thomas Leggett's net worth?

How old is Thomas Leggett?

How do I contact Thomas Leggett?

Has Thomas Leggett been buying or selling shares of Stoke Therapeutics?

Who are Stoke Therapeutics' active insiders?

Are insiders buying or selling shares of Stoke Therapeutics?